Proactive Investors - Run By Investors For Investors

Pfizer quarterly revenue falls more than forecast on lower demand for Prevnar and Enbrel

Pfizer has raised its earnings guidance and expects up to 30 approvals for its pipeline of medicines over the next five years
Pfizer's second quarter earnings were ahead of analysts' expectations

Pfizer Inc. (NYSE:PFE) reported a worse-than-expected decline in second quarter revenue as demand for its pneumonia vaccine Prevnar and rheumatoid arthritis treatment Enbrel waned.

Revenue fell 2% to US$12.9bn in the second quarter from US$13.15bn in the year ago period, missing analysts’ estimates of US$13.07bn.  Pfizer said revenues incurred a US$202mln impact of foreign exchange headwinds and were also affected by the sale of its global infusion therapy net assets, Hospira Infusion Systems (HIS) in February.

Earnings were ahead of expectations, however, as the company managed its costs.

Net income rose to US$3.07bn, or 51 cents per share, from US$2.05bn, of 33 cents per share.

Adjusted earnings per share (EPS) was 67 cents, up from 64 cents the prior period and compared to market forecasts of 65 cents.

The company raised its 2017 adjusted EPS guidance to a range of US$2.54 to US$2.60 from a previous estimate of US$2.50 to US$2.60.

“I am pleased with our second-quarter 2017 results and our year-to-date performance is in line with our expectations,” said chief executive Ian Read.

Read said the company has a strong pipeline of drugs and expects about 25 to 30 regulatory approvals over the next five years.  Up to 15 of these have the potential to be blockbusters, of which half could receive approval by 2020, Read said.

“Our strategy remains focused on maximising in-market opportunities while continuing to advance the pipeline and managing our cost structure to deliver attractive financial performance over time.”

Shares in the company fell 0.185 to US$33.10 each in US pre-market trading. 

View full PFE profile View Profile

Pfizer Timeline

November 23 2015

Related Articles

June 27 2018
Ridinilazole is a possible treatment for C. Difficile and Summit hopes to kick off a phase III trial in the first quarter of 2019
DNA sequence
July 12 2018
The cell therapy specialist also reported there had been industry interest around its main programmes
little girl sneezing in a field
May 21 2018
The Phase II study of Allergy Therapeutics’ PQ Grass immunotherapy – an aluminium-free, ultra-short course hay fever treatment – evaluated dose response and safety

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use